Refractory Multiple Myeloma Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Refractory Multiple Myeloma Market Overview
The Global Refractory Multiple Myeloma Market has grown substantially, reaching USD 2.4 billion in 2022 and is projected to expand further, estimated to reach USD 3.4 billion by 2030, with a CAGR of 4.7% during the forecast period from 2023 to 2030. Refractory multiple myeloma, resistant to treatment or worsening post-treatment, is driving the market growth due to rising incidence rates and research and development efforts.

Market Scope

Segments Covered: Drug Type, Route of Administration, Product Type, End User, and Region.
Regional Coverage: North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
Insights Covered: Competitive Landscape, Market Size, Share, Growth Drivers & Restraints, Recent Developments, Regulatory Analysis, and Supply Chain Insights.

Market Dynamics: Drivers and Restraints

Novel Product Launches: The introduction of new drugs and ongoing research & development is propelling market growth. Recent launches like Fresenius Kabi's Bortezomib for Injection and Pfizer Inc.'s Elranatamab illustrate this trend.

Regulatory Approvals and Pipeline Development: Rising regulatory approvals and active clinical trials by key players like Pfizer Inc. are driving market opportunities. The FDA's Breakthrough Therapy Designation for Elranatamab is a significant development.

Cost Challenges: The high cost associated with treatment, such as stem cell transplants, affects the market growth. This challenges affordability and accessibility, especially in regions like India.

Request For Free Sample: https://www.datamintelligence.com/download-sample/refractory-multiple-myeloma-market
Market Segment Analysis

Dominant Segment: Proteasome Inhibitors hold a significant market share (38.8%) and are expected to continue growing due to their efficacy in blocking NF-kB signaling, leading to anti-myeloma effects.
Geographical Analysis

North America's Dominance: North America holds a considerable share (42.7%) due to established healthcare infrastructure, key players, and increasing demand for refractory multiple myeloma treatments.
COVID-19 Impact Analysis

Moderate Impact: While the Russia-Ukraine conflict may impact import/export of raw materials, the overall impact on the global market is projected to be limited due to the low prevalence in these regions.
Competitive Landscape

Major Players: Key players include Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., among others, actively involved in developing treatments for refractory multiple myeloma.
Key Developments

Recent Advancements: Notable studies and approvals include Janssen Pharmaceutical's filing of a supplementary application for CARVYKTI and Bristol Myers Squibb's approval for supplemental Biologics.
North America remains dominant due to its robust infrastructure and key players' presence. Proteasome Inhibitors are a significant segment, expected to continue growth due to their efficacy. The market has witnessed significant developments in terms of CAR-T therapy and other immunomodulatory treatments.

Related Reports:

https://www.datamintelligence.com/download-sample/multiple-myeloma-market
https://www.datamintelligence.com/download-sample/multiple-myeloma-market
https://www.datamintelligence.com/download-sample/myomectomy-market

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.